The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus

Rheumatology

Volumn 38, Issue 11, 1999, Pages 1130-1137

  Sutcliffe, N ^a,d   Clarke, A E ^b   Gordon, C ^c   Farewell, V ^a   Isenberg, D A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Centre for Rheumatology   (United Kingdom)

Author keywords

Disease activity; Organ damage; Psychosocial factors; Race; SLE; Socio economic status

Indexed keywords

ADULT; AGED; ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; EDUCATION; EMPLOYMENT; FEMALE; HEALTH CARE ACCESS; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RACE; SOCIAL PSYCHOLOGY; SOCIAL STATUS; SOCIAL SUPPORT; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME; UNITED KINGDOM;

EID: 0032699813     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.11.1130     Document Type: Article

References (26)

1. Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1995;7:402-8.
2. Bombardier C, Gladman DD, Urowitz MB, Channon D, Chang CH and the Committee on Prognosis Studies in SLE. The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992; 35:630-40.
3. Sutcliffe N, Clarke AE, Levinton C, Frost C, Gordon C, Isenberg DA. Associates of health status in patients with systemic lupus erythematosus. J Rheumatol 1999; in press.
4. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
5. Gladman DD. Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1994;6:487-92.
6. Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
7. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Fossel AE et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:47-56.
8. Clarke AE, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL et al. An international perspective on the well-being and health care costs for patients with systemic lupus erythematosus. J Rheumatol 1999;26:1500-11.
9. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. Clarke A, Esdaile J, Bloch D, Lacaille, Danoff D, Fries J. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548-59.
11. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: Internal validation. J Rheumatol 1994;21:1468-71.
12. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg et al. Cross cultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992;19:608-11.
13. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997;24:309-13.
14. Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248-54.
15. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
16. Revenson TA. The role of social support with rheumatic disease. Baillière's Clin Rheumatol 1993;7:377-96.
17. Cohen S, Mermelstein R, Kamack T, Hoberman HM. Measuring the functional components of social support. In: Sarason IG, Sarason BR, eds. Social support: theory, research and applications. The Hague: Martinus Nijhoff, 1985:73-94.
18. Ware JE Jr, Snyder MK, Wright R, Davies AR. Defining and measuring patient satisfaction with medical care. Eval Program Plann 1983;6:247-63.
19. McCullagh P. Regression models for ordinal data (with discussion). J R Stat Soc B 1980;42:109-42.
20. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-8.
21. Johnson AE, Gordon C, Palmer RG, Bacon PA. SLE disease activity among different ethnic groups in Birmingham, UK. Br J Rheumatol 1993;32:30.
22. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990;33:37-48.
23. Ward MM, Pyun E, Studenski S. Long term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
24. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Roberts WN et al. The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus. Arthritis Rheum 1995;38:267-73.
25. Reveille JD, Moulds JM, Ahn C et aL Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA Class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998;41:1161-72.
26. Alarcon GS, Roseman J, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups. II. Features predictive of disease activity early in its course. Arthritis Rheum 1998;41:1173-80.